Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:9989
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 726 out of 850
Universe
Global Universe 13103 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Almirall SA |
16.3
Low
|
34 out of 850 |
Grand Pharmaceutical Group Ltd. |
31
High
|
532 out of 850 |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. |
33
High
|
610 out of 850 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. |
36
High
|
726 out of 850 |
Chongqing Taiji Industry (Group) Co., Ltd. |
42.7
Severe
|
843 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Management of ESG Material Risk is Average